JenKem Technology
Explore the latest insights on JenKem Technology and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of JenKem Technology’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Sunshine Guojian Posts 24.77% Revenue Growth in First Three Quarters of 2026 as Anmuquitamab and Anfrequitamab Approvals Reshape Its Autoimmune Franchise
Sunshine Guojian Pharmaceutical Co., Ltd. (SHA: 688336) released its third‑quarter 2026 report, recording total revenue of RMB 1.392 billion (up 24.77% year‑over‑year) and net profit attributable to shareholders of RMB…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
